+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Ocaliva"

OCALIVA Market Size, Forecast, and Drug Insight - 2032 - Product Thumbnail Image

OCALIVA Market Size, Forecast, and Drug Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027) - Product Thumbnail Image

Global Non-Alcoholic Steatohepatitis Market (by Drug Type, Application Type, Distribution Type, & Region): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)

  • Report
  • November 2023
  • 130 Pages
  • Global
From
NASH Treatment & Therapeutics Market Report 2023-2033 - Product Thumbnail Image

NASH Treatment & Therapeutics Market Report 2023-2033

  • Report
  • July 2023
  • 224 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024

  • Report
  • February 2024
  • 200 Pages
  • Global
From
Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2023-2028 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis Market by Drug Type, Disease Cause, Sales Channel, End User, and Region 2023-2028

  • Report
  • May 2023
  • 142 Pages
  • Global
From
UDCA Market Size, Forecast, and Drug Insight - 2032 - Product Thumbnail Image

UDCA Market Size, Forecast, and Drug Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
Global Primary Biliary Cholangitis Therapeutics Market - Product Thumbnail Image

Global Primary Biliary Cholangitis Therapeutics Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Nonalcoholic Steatohepatitis (NASH): Update Bulletin - Product Thumbnail Image

Nonalcoholic Steatohepatitis (NASH): Update Bulletin

  • Newsletter
  • April 2024
  • Global
From
Global NASH Market - Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026) - Product Thumbnail Image

Global NASH Market - Analysis By Drug Type, Sales Chanel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Impact, Competition and Forecast (2021-2026)

  • Report
  • March 2021
  • 210 Pages
  • Global
From
Global Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type, By Application Type, By Distribution Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027 - Product Thumbnail Image

Global Non-Alcoholic Steatohepatitis Market: Analysis By Drug Type, By Application Type, By Distribution Type, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027

  • Report
  • January 2023
  • 130 Pages
  • Global
From
Primary Biliary Cholangitis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Primary Biliary Cholangitis - Epidemiology Forecast - 2032

  • Report
  • February 2023
  • 97 Pages
  • Global
From
Primary Biliary Cholangitis - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

Primary Biliary Cholangitis - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • February 2023
  • 195 Pages
  • Global
From
Global Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Application, and Sales Channel - Product Thumbnail Image

Global Non-Alcoholic Steatohepatitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product, Application, and Sales Channel

  • Report
  • April 2022
  • 178 Pages
  • Global
From
Primary Biliary Cholangitis (PBC) Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) - Product Thumbnail Image

Primary Biliary Cholangitis (PBC) Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • Report
  • January 2022
  • 110 Pages
  • Global
From
Disruptive Innovations Fueling Improved NASH Management - Product Thumbnail Image

Disruptive Innovations Fueling Improved NASH Management

  • Report
  • March 2020
  • 48 Pages
  • Global
From
Liver Fibrosis - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

Liver Fibrosis - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • August 2022
  • 239 Pages
  • Global
From
Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038 - Product Thumbnail Image

Non-alcoholic steatohepatitis (NASH) Market and Forecast Analysis to 2038

  • Report
  • January 2021
  • 102 Pages
  • Global
Ocaliva (obeticholic acid; Intercept Pharmaceuticals) Drug Overview 2019 - Product Thumbnail Image

Ocaliva (obeticholic acid; Intercept Pharmaceuticals) Drug Overview 2019

  • Report
  • July 2019
  • 17 Pages
  • Global
Non-Alcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2029 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2029

  • Report
  • November 2020
  • 140 Pages
  • Global
From
Loading Indicator

Ocaliva is a drug used to treat primary biliary cholangitis (PBC), a chronic liver disorder, and polycystic kidney disease (PKD), a genetic disorder that affects the kidneys. It is a small molecule inhibitor of the enzyme farnesoid X receptor (FXR), which is involved in the regulation of bile acid metabolism. Ocaliva is the only approved FXR agonist for the treatment of PBC and PKD. It is available in both oral and intravenous formulations. Ocaliva is marketed by Intercept Pharmaceuticals, a biopharmaceutical company based in the United States. Other companies in the market include Gilead Sciences, Merck, and Novartis. Show Less Read more